LeonaBio
LeonaBio, headquartered in the Seattle, Washington area, is a clinical-stage biopharmaceutical company developing novel therapeutics for diseases with high unmet medical needs, including treatment-resistant metastatic breast cancer and ALS. Our lead drug candidates, lasofoxifene and ATH-1105, are novel, small molecule therapies with the potential to address devastating diseases where treatment options are limited or ineffective. We are committed to scientific excellence and patient-centered innovation to deliver meaningful new therapies for those who need them most.
